We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+47.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$367M
AUM Growth
-$744K
(-0.2%)
Cap. Flow
-$75M
Cap. Flow
% of AUM
-20.41%
Top 10 Holdings %
Top 10 Hldgs %
48.04%
Holding
60
New
17
Increased
14
Reduced
15
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
+$9.03M |
| 2 |
Replimune Group
REPL
|
+$8.65M |
| 3 |
VistaGen Therapeutics
VTGN
|
+$6.38M |
| 4 |
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
|
+$5.73M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$4.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$43.5M |
| 2 |
Kura Oncology
KURA
|
+$11.8M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$10.2M |
| 4 |
Cytokinetics
CYTK
|
+$7.74M |
| 5 |
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
|
+$7.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.24% |
| 2 | Financials | 4.13% |
| 3 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Novavax
NVAX
$1.31B
| $279K | 0.08% |
+2,500
| New | +$266K |
|
52
BioCryst Pharmaceuticals
BCRX
$2.4B
| – | – |
-660,000
| Closed | -$2.27M |
|
53
Cogent Biosciences
COGT
$7.24B
| – | – |
-102,500
| Closed | -$959K |
|
54
Cardiff Oncology
CRDF
$77.2M
| – | – |
-305,900
| Closed | -$4.34M |
|
|
55
Cytokinetics
CYTK
$10.4B
| – | – |
-357,500
| Closed | -$7.74M |
|
56
Cartesian Therapeutics
RNAC
$268M
| – | – |
-78,807
| Closed | -$5.86M |
|
57
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| – | – |
-250,000
| Closed | -$27.9M |
|
|
PANA.U
58
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
| – | – |
-280,000
| Closed | -$3.36M |
|
|
LSACU
59
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| – | – |
-560,000
| Closed | -$7.62M |
|
|
IMMU
60
DELISTED
Immunomedics Inc
IMMU
| – | – |
-511,500
| Closed | -$43.5M |
|
Similar funds
EC
YEPX
SR
IA
VVM
POIA
TM
KCM
Acuta Capital Partners's Q4 2020 Portfolio in Review
As of Q4 2020, Acuta Capital Partners held 60 positions worth $367M, down 0.2% from $368M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Acuta Capital Partners withdrew a net $75M in Q4 2020, closing 9 positions and reducing 15 holdings. Its most notable exit was Immunomedics Inc, an estimated $43.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.
Against the trend, Acuta Capital Partners opened a new position in BCLS Acquisition Corp. Class A Ordinary Shares worth $9.38M.
- Acuta Capital Partners's largest Q4 2020 buy was BCLS Acquisition Corp. Class A Ordinary Shares: 842,500 shares worth $9.38M.
- Acuta Capital Partners added most to Syndax Pharmaceuticals in Q4 2020, an estimated $4.66M increase.
- Acuta Capital Partners's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $11.8M.
- Acuta Capital Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $43.5M.
- Acuta Capital Partners's ten largest holdings make up 48% of its $367M portfolio in Q4 2020.
- Acuta Capital Partners opened 17 new positions and closed 9 in Q4 2020.
- Acuta Capital Partners's portfolio value fell 0.2% quarter-over-quarter to $367M.
Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.